Ultrashort peptide bioconjugates are exclusively antifungal agents and synergize with cyclodextrin and amphotericin B

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 1-9

  Arnusch, Christopher J ^a   Ulm, Hannah ^b   Josten, Michaele ^b   Shadkchan, Yana ^c   Osherov, Nir ^c   Sahl, Hans Georg ^b   Shai, Yechiel ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF BONN   (Germany)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

9H FLUOREN 9 YLMETHOXYCARBONIC ACID; ADAMANTANECARBOXYLIC ACID; ALPHA TOCOPHEROL; ALPHA TOCOPHEROL SUCCINATE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BETA CYCLODEXTRIN; BIOTIN; CARBONIC ACID; CARBOXYLIC ACID; CHOLESTEROL; CHOLESTERYLCARBONIC ACID; CYCLODEXTRIN; FATTY ACID; LIPOPEPTIDE; PALMITIC ACID; UNCLASSIFIED DRUG; VITAMIN E KAAK; VITAMIN E KKKK;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; BIOCOMPATIBILITY; CANDIDA ALBICANS; CELL DAMAGE; CELL MEMBRANE; CRYPTOCOCCUS NEOFORMANS; CYTOTOXICITY TEST; DRUG DESIGN; DRUG SYNTHESIS; ERYTHROCYTE; FEMALE; HYDROPHOBICITY; LIPOPHILICITY; MACROPHAGE; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY;

AMPHOTERICIN B; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ASPERGILLUS FUMIGATUS; BACTERIA; BETA-CYCLODEXTRINS; CANDIDA ALBICANS; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CHOLESTEROL; CRYPTOCOCCUS NEOFORMANS; DRUG SYNERGISM; ERYTHROCYTES; HEMOLYSIS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MACROPHAGES; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, TRANSMISSION; MYCOSES; SPECIES SPECIFICITY; STATIC ELECTRICITY; VITAMIN E;

EID: 84455161753     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00468-11     Document Type: Article

References (44)

1. Arnusch CJ, et al. 2007. Enhanced membrane pore formation by multimeric/oligomeric antimicrobial peptides. Biochemistry 46:13437-13442. (Pubitemid 350136382)
2. Avrahami D, Shai Y. 2003. Bestowing antifungal and antibacterial activities by lipophilic acid conjugation to D,L-amino acid-containing antimicrobial peptides: a plausible mode of action. Biochemistry 42:14946-14956. (Pubitemid 37553525)
3. Bechinger B. 1999. The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy. Biochim. Biophys. Acta 1462:157-183.
4. Challa R, Ahuja A, Ali J, Khar RK. 2005. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech. 6:E329-E357.
5. Chen Y, et al. 2007. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. Antimicrob. Agents Chemother. 51:1398-1406. (Pubitemid 46586822)
6. Chongsiriwatana NP, et al. 2011. Short alkylated peptoid mimics of antimicrobial lipopeptides. Antimicrob. Agents Chemother. 55:417-420.
7. Chu-Kung AF, Nguyen R, Bozzelli KN, Tirrell M. 2010. Chain length dependence of antimicrobial peptide-fatty acid conjugate activity. J. Colloid. Interface Sci. 345:160-167.
8. Clinical Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement (M100-S15), vol. 30. Clinical Laboratory Standards Institute, Wayne, PA.
9. Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A2, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Davis ME, Brewster ME. 2004. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 3:1023-1035. (Pubitemid 39642365)
12. Eisen MB, Spellman PT, Brown PO, Botstein D. 1998. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95:14863-14868. (Pubitemid 29003722)
13. Epand RM. 1997. Biophysical studies of lipopeptide-membrane interactions. Biopolymers 43:15-24. (Pubitemid 127570808)
14. Epand RM, et al. 2010. Lipid clustering by three homologous argininerich antimicrobial peptides is insensitive to amino acid arrangement and induced secondary structure. Biochim. Biophys. Acta 1798:1272-1280.
15. Faber C, et al. 2003. Release of antimicrobial peptide Dhvar-5 from polymethylmethacrylate beads. J. Antimicrob. Chemother. 51:1359-1364. (Pubitemid 36748923)
16. Friedrich CL, Moyles D, Beveridge TJ, Hancock RE. 2000. Antibacterial action of structurally diverse cationic peptides on gram-positive bacteria. Antimicrob. Agents Chemother. 44:2086-2092. (Pubitemid 30484431)
17. Groll AH, McNeil Grist L. 2009. Current challenges in the diagnosis and management of invasive fungal infections: report from the 15th International Symposium on Infections in the Immunocompromised Host: Thessaloniki, Greece, 22-25 June 2008. Int. J. Antimicrob. Agents 33:101-104.
18. Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557. (Pubitemid 44967479)
19. Hilpert K, et al. 2010. Short cationic antimicrobial peptides interact with ATP. Antimicrob. Agents Chemother. 54:4480-4483.
20. Lohner K, Blondelle SE. 2005. Molecular mechanisms of membrane perturbation by antimicrobial peptides and the use of biophysical studies in the design of novel peptide antibiotics. Comb. Chem. High Throughput Screen. 8:241-256. (Pubitemid 40488604)
21. Makovitzki A, Avrahami D, Shai Y. 2006. Ultrashort antibacterial and antifungal lipopeptides. Proc. Natl. Acad. Sci. U. S. A. 103:15997-16002. (Pubitemid 44657581)
22. Makovitzki A, Baram J, Shai Y. 2008. Antimicrobial lipopolypeptides composed of palmitoyl Di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry 47:10630-10636.
23. Makovitzki A, Fink A, Shai Y. 2009. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res. 69:3458-3463.
24. Minamoto GY, Rosenberg AS. 1997. Fungal infections in patients with acquired immunodeficiency syndrome. Med. Clin. North Am. 81:381-409. (Pubitemid 27150285)
25. Oren Z, Shai Y. 1998. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 47:451-463.
26. Pappas PG, et al. 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin. Infect. Dis. 50:1101-1111.
27. Park Y, Hahm KS. 2005. Antimicrobial peptides (AMPs): peptide structure and mode of action. J. Biochem. Mol. Biol. 38:507-516.
28. Peschel A, Sahl HG. 2006. The co-evolution of antimicrobial host defense peptides and microbial peptide resistance. Nat. Rev. Microbiol. 4:529-536. (Pubitemid 43905612)
29. Pieters RJ, Arnusch CJ, Breukink E. 2009. Membrane permeabilization by multivalent anti-microbial peptides. Protein Pept. Lett. 16:736-742.
30. Pihet M, et al. 2009. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis-a review. Med. Mycol. 47:387-397.
31. Porter EA, Wang X, Lee HS, Weisblum B, Gellman SH. 2000. Nonhaemolytic beta-amino-acid oligomers. Nature 404:565.
32. Radzishevsky IS, et al. 2007. Improved antimicrobial peptides based on acyl-lysine oligomers. Nat. Biotechnol. 25:657-659. (Pubitemid 46897206)
33. Reddy KV, Yedery RD, Aranha C. 2004. Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Agents 24:536-547. (Pubitemid 39536106)
34. Rosenfeld Y, Papo N, Shai Y. 2006. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides: peptide properties and plausible modes of action. J. Biol. Chem. 281:1636-1643.
35. Segal BH, et al. 2007. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin. Infect. Dis. 44:402-409. (Pubitemid 46147624)
36. Soares AF, Carvalho Rde A, Veiga F. 2007. Oral administration of peptides and proteins: nanoparticles and cyclodextrins as biocompatible delivery systems. Nanomedicine (London) 2:183-202. (Pubitemid 46845766)
37. Spikes S, et al. 2008. Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J. Infect. Dis. 197:479-486. (Pubitemid 351263432)
38. Stergiopoulou T, et al. 2009. Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J. Antimicrob. Chemother. 63:343-348.
39. Toke O. 2005. Antimicrobial peptides: new candidates in the fight against bacterial infections. Biopolymers 80:717-735. (Pubitemid 43266580)
40. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. 2008. Amphotericin B formulations and drug targeting. J. Pharm. Sci. 97:2405-2425.
41. Tossi A, Sandri L, Giangaspero A. 2000. Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 55:4-30.
42. Vallon-Eberhard A, et al. 2008. Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyllys- ala-DAla-lys. Antimicrob. Agents Chemother. 52:3118-3126.
43. White RL, Burgess DS, Manduru M, Bosso JA. 1996. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob. Agents Chemother. 40:1914-1918. (Pubitemid 26277815)
44. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395. (Pubitemid 34100944)